Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib

Ali, Naveed; Pickens, Peter V.; Auerbach, Herbert E.

doi:10.4081/hr.2016.6295

Open AccessCase Report

Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib

by

Naveed Ali

^1,*,

Peter V. Pickens

² and

Herbert E. Auerbach

³

¹

Department of Internal Medicine, Abington Memorial Hospital/Abington-Jefferson Health, 1200 Old York Road, Abington, PA 19001, USA

²

Department of Hematology and Oncology, Abington Memorial Hospital/Abington Jefferson Health, Abington, PA 19001, USA

³

Department of Pathology, Abington Memorial Hospital/Abington-Jefferson Health, Abington, PA 19001, USA

^*

Author to whom correspondence should be addressed.

Hematol. Rep. 2016, 8(1), 6295; https://doi.org/10.4081/hr.2016.6295

Submission received: 4 November 2015 / Revised: 19 January 2016 / Accepted: 19 January 2016 / Published: 17 March 2016

Download

Abstract

Multiple myeloma (MM) is a neoplastic lymphoproliferative disorder characterized by uncontrolled monoclonal plasma cell proliferation. Among different isotypes of MM, immunoglobulin D (IgD) MM is very rare, representing only 1 to 2% of all isotypes. Chronic myelogenous leukemia (CML) is a neoplastic myeloproliferative disorder of pluripotent hematopoietic stem cell, which is characterized by the uncontrolled proliferation of myeloid cells. An 88-year-old male was diagnosed simultaneously with IgD kappa MM and CML. A distinctive feature in this patient was the progression to plasma cell leukemia without any symptomatic myeloma stage. He was treated simultaneously with lenalidomide, bortezomib and imatinib. Synchronous occurrence of these rare hematological malignancies in a single patient is an exceedingly rare event. Multiple hypotheses to explain co-occurrence of CML and MM have been proposed; however, the exact etiological molecular pathophysiology remains elusive.

Keywords: immunoglobulin D multiple myeloma; plasma cell leukemia; chronic myelogenous leukemia; bortezomib; imatinib

Share and Cite

MDPI and ACS Style

Ali, N.; Pickens, P.V.; Auerbach, H.E. Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib. Hematol. Rep. 2016, 8, 6295. https://doi.org/10.4081/hr.2016.6295

AMA Style

Ali N, Pickens PV, Auerbach HE. Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib. Hematology Reports. 2016; 8(1):6295. https://doi.org/10.4081/hr.2016.6295

Chicago/Turabian Style

Ali, Naveed, Peter V. Pickens, and Herbert E. Auerbach. 2016. "Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib" Hematology Reports 8, no. 1: 6295. https://doi.org/10.4081/hr.2016.6295

APA Style

Ali, N., Pickens, P. V., & Auerbach, H. E. (2016). Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib. Hematology Reports, 8(1), 6295. https://doi.org/10.4081/hr.2016.6295

Article Menu

Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI